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Summary 26 
Novel analytical measures are needed to accurately monitor the properties of platelet 27 
concentrates (PC). Since activated platelets produce platelet-derived extracellular 28 
vesicles (EVs), analysing EVs of PCs may provide additional information about the 29 
condition of platelets. The prospect of using EVs as auxiliary measure of platelet 30 
activation state was investigated by examining the effect of platelet additive solutions 31 
(PAS) on EV formation and platelet activation during PC storage. 32 
The time-dependent activation of platelets in PCs with PAS-B or with the further 33 
developed PAS-E was compared by measuring the exposure of CD62P by flow cytometry 34 
and the content of soluble glycoprotein V (sGPV) of PCs by an immunoassay. Changes 35 
in the concentration and size distribution of EVs were determined using nanoparticle 36 
tracking analysis. 37 
A time-dependent increase of platelet activation in PCs was demonstrated by the 38 
increased CD62P exposure, sGPV content, and EV concentration. Using these strongly 39 
correlating parameters, PAS-B platelets were shown to be more activated compared to 40 
PAS-E platelets. 41 
Since the pEV concentration correlated well with the established platelet activation 42 
markers CD62P and sGPV, it could potentially be used as a complementary parameter 43 
for platelet activation for PCs. More detailed characterization of the resulting EVs could 44 
help to understand how the PC components contribute the functional effects of transfused 45 
PCs. 46 
 47 
 48 
 49 
 50 
 51 
 52 
Keywords 53 
Platelet concentrate; extracellular vesicle; platelet activation; platelet additive solution; 54 
CD62P; soluble glycoprotein V  55 
3 
 
1 Introduction 56 
Platelet concentrates (PC) are manufactured for patients with haemostatic problems, e.g., 57 
excessive bleeding or thrombocytopenia in cancer. The average lifespan of a platelet in 58 
blood circulation is 10 days [1], and the storage time of PC is typically 5 to 7 days [2] 59 
mainly due to an increased risk of bacterial contamination during extended storage at 60 
room temperature [3]. Efforts are made to increase the storage time of PCs by developing 61 
the platelet additive solutions (PAS), improving protocols in the PC preparation, pathogen 62 
inactivation and by more detailed quality control (QC) [4–6].  63 
A crucial aspect of QC of PCs is the determination of platelet activation state. One widely 64 
used marker of platelet activation is P-selectin (CD62P) exposure of platelets. CD62P is 65 
transferred to the platelet plasma membrane through the fusion of ɑ-granules upon 66 
activation [7]. Another platelet-specific marker is the soluble form of glycoprotein V 67 
(sGPV), which is released from activated platelets through proteolytic cleavage [8]. The 68 
transmembrane form of glycoprotein V is located on the platelet surface as a part of a 69 
complex with glycoproteins Ib and IX, which is the major receptor for von Willebrand 70 
factor [9] and it also participates in thrombin [10] and collagen [11] binding. Other current 71 
QC assays of PCs include the quantification of platelet metabolites (glucose, lactate, pH) 72 
and dissolved gases (pO2, pCO2), and the determination of platelet function using the 73 
extent of shape change and hypotonic shock response. Also, different platelet parameters, 74 
such as the mean platelet volume and platelet count are commonly monitored to examine 75 
the quality of platelets [6]. 76 
Besides the platelets' main role in regulation of haemostasis, they have been shown to 77 
influence immune responses [7], which is an aspect to consider when platelet concentrates 78 
are administered to patients. During storage of PCs, platelets liberate a large variety of 79 
bioactive components that have been proposed to relate to adverse pro-inflammatory 80 
effects observed in storage lesion [12,13]. Although several different markers for 81 
measuring storage lesion have been suggested, a gold standard to evaluate the usability 82 
of PCs for transfusion has not yet been established [6]. Therefore, novel markers are 83 
needed to assess the condition of platelets in more detail. 84 
Besides platelets, the PCs contains extracellular vesicles (EVs), which in majority are 85 
derived from platelets, but which also originate from red blood cells and leukocytes 86 
residually present in the plasma fraction of PCs [14]. One of the first functions in which 87 
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platelet-derived EVs were shown to participate in was haemostasis [15,16], implemented 88 
by the interaction of coagulation factors on the phosphatidylserine surface of the EVs 89 
[17]. Additionally EVs are considered to be biomarkers of thrombotic and inflammatory 90 
diseases, as well as cancer [18,19], and in general EVs have already been shown to 91 
mediate several (patho)physiological processes [20,21]. Furthermore, EVs have been 92 
suggested to contribute to the adverse transfusion-related reactions [22], underscoring the 93 
need to understand the possible effector functions of EVs in transfusion. In addition to 94 
the possible effects of the transfused EVs in patients, EV generation during the storage of 95 
PCs could be considered as auxiliary parameter to monitor the activation state of platelets, 96 
since the generation of platelet-derived EVs is dependent on the aging and activation 97 
status of platelets [23,24]. 98 
In the current study, EVs of PC were quantified to see whether the EV content could be 99 
utilized as a parameter of the activation state of platelets in PCs together with the 100 
recognized platelet activation markers, CD62P exposure of platelets and the sGPV 101 
content. This was investigated by examining the platelet activation state in aging PCs 102 
with different PAS. 103 
2 Materials and Methods 104 
2.1 Sample Collection 105 
Standard leukocyte-reduced PCs each derived from buffy coats of four ABO RhD - 106 
matched whole blood donations with platelet additive solution B (PAS-B) or platelet 107 
additive solution E (PAS-E) were obtained from the Finnish Red Cross Blood Service 108 
(Helsinki, Finland) and were handled anonymously, as accepted by Finnish Supervisory 109 
Authority for Welfare and Health (Valvira, Helsinki, Finland). The exact composition of 110 
PAS-B and PAS-E, also known as PAS-2 and modified PAS-3 [25], respectively, have 111 
been reported elsewhere [26]. 112 
Sterile sampling was done using 50 mL syringes (Henke-Sass, Wolf GmbH, Tuttlingen, 113 
Germany) and 18-gauge needles (Terumo, Tokyo, Japan). Before sampling, the contents 114 
of the storage bag’s tube were emptied into the storage bag and the PC was mixed by 115 
gently turning it from side to side 5 times. This procedure was repeated 3 times to obtain 116 
a representative sample. After extracting 20 mL of sample via the storage bag’s tube, the 117 
tube was resealed. The sampling days (d) were d1, d2, d5, and d8 counting from the blood 118 
donation (d0), where d1 was the production day of PC. The d1 sampling was performed 119 
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within 2 hours after the PCs were available from the production line, approximately at 3 120 
p.m., whereas the d2 - d8 samplings were performed at 9 a.m. PCs were stored at 22 °C 121 
under constant horizontal agitation. 122 
2.2 Determination of CD62P Exposure of Platelets 123 
The CD62P expression on the platelet surface was determined by flow cytometry using 1 124 
mL of PC sample. PC samples were diluted 1:100 (to approx. 1 × 107 per mL) using a 125 
diluent consisting of the same PAS used for PC production (either PAS-B or PAS-E; SSP 126 
or SSP+, (Macopharma, Tourcoing, France)) with 0.5% w/v Bovine Serum Albumin 127 
(Sigma-Aldrich, St. Louis, MO, USA). 50 µL of diluted PC sample was labelled using 128 
2 µL of fluorescein isothiocyanate (FITC)-coupled anti-CD41 (FITC Mouse Anti-Human 129 
CD41, clone HIP8 (Becton Dickinson, Franklin Lakes, NJ, USA)) and 5 µL of 130 
phycoerythrin-cyanine 5 (PE-Cy5)-coupled anti-CD62P (PE-Cy5 Mouse Anti-Human 131 
CD62P, clone AK-4 (Becton Dickinson)). For each sample an isotype control sample 132 
(50 µL of diluted PC sample labelled with 5 µL of PE-Cy5 Mouse IgG1 κ isotype control, 133 
clone MOPC-21 (Becton Dickinson)) and a thrombin activated positive control sample 134 
with maximum CD62P expression (50 µL of diluted PC sample labelled with 2 µL of 135 
CD41-FITC and 5 µL of CD62P-PE-Cy5 and activated with 1 IU/mL thrombin (Roche, 136 
Basel, Switzerland)) were prepared. Samples and controls were labelled and analysed in 137 
BD TruCount-tubes (Becton Dickinson) containing a known number of fluorescent 138 
beads. Samples were analysed in singlicates, since previously the CD62P measurements 139 
had been found well repeatable [27]. After labelling samples were mixed, incubated for 140 
20 minutes at room temperature (RT) in the dark, further diluted with 500 µL of diluent, 141 
and stored in the dark until analysis. 142 
The samples and controls were analysed with Navios flow cytometer (Beckman Coulter, 143 
Brea, CA, USA) at “high-flow” speed. The forward (FS) and side scatter detectors’ (SS) 144 
volt and gain settings had been adjusted such that the platelet population was centred in 145 
the FS –SS dot plot (at around 101) and the fluorescence detectors’ FL1 (FITC) and FL4 146 
(PE-Cy5) settings such that the detected fluorescence signals were well within the 147 
displayed ranges for all samples. The TruCount beads were gated based on their 148 
fluorescence in FL1, FL2 and FL3 channels and a platelet gate had been defined in the 149 
FL1 – SS dot plot. For each sample 5000 bead events were acquired, corresponding to 150 
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about 60000 platelet events. The gated platelet population was used to calculate the 151 
percentage of CD62P positive platelets, defined as: 152 
- Based on the isotype control, a threshold was set to include 1% of all events with 153 
the highest fluorescence in the FL4-channel. All events with FL4-fluorescence 154 
above this threshold were defined as CD62P positive in comparison to the isotype 155 
control. 156 
- Based on the positive control, a threshold was defined to include 95% of the 157 
thrombin activated platelet population with the highest fluorescence. All platelets 158 
with FL4-fluorescence above this threshold were considered CD62P positive in 159 
comparison to the positive control. 160 
Platelet activation state was expressed in relation to both isotype and positive control as 161 
percentage of gated platelet population above the respective CD62P positivity threshold. 162 
2.3 Quantification of sGPV 163 
The quantification of soluble glycoprotein V (sGPV) was performed as reported 164 
previously [6]. Briefly, 1 mL of the PC was centrifuged (Biofuge 13 (Heraeus Sepatech, 165 
Hanau, Germany)) first at 3600 × g in RT for 15 minutes and the supernatant again at 166 
11000 × g in RT for 5 minutes (Biofuge 13). The supernatant was transferred to new tubes 167 
in 500 µL aliquots and stored at -70 °C until sGPV quantification with a commercial kit 168 
(Asserachrom, Diagnostica Stago, France). For the measurement, samples were diluted 169 
1:80 - 1:640 using phosphate buffer provided with the kit, and the amount of sGPV was 170 
expressed as pmol/109 platelets. 171 
2.4 Isolation of EVs 172 
A total of 17 mL of PC was used for EV isolation. To prevent platelet activation, 173 
Anticoagulant Citrate Dextrose Solution pH Eur Solution A (Terumo BCT, Lakewood, 174 
CO, USA) and Apyrase (Sigma-Aldrich) were added to the final concentrations of 4.25% 175 
v/v and 2 U/mL, respectively, and the PC was diluted 1:4 with phosphate buffered saline 176 
(PBS (Thermo Fisher, Waltham, MA, USA)). The diluted PC was centrifuged at 650 × g 177 
at RT for 7 minutes (Eppendorf centrifuge 5810R, (Eppendorf, Hamburg, Germany)) 178 
without brake, and the supernatant was centrifuged 1560 × g in RT for 20 minutes 179 
(Eppendorf centrifuge 5810R). The residual platelet content of the supernatant was 180 
reduced to 1 × 106 platelets/mL, as confirmed with Coulter Cell counter T-540 (Beckman 181 
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Coulter). To extract the whole EV population from the PC, the supernatant was 182 
ultracentrifuged at 100000 × g at 4 °C for 1 hour (MLA-50 rotor, k-factor 92 (Beckman 183 
Coulter)). The supernatant was carefully decanted and remaining supernatant was 184 
removed with a pipette, after which the EV sample was resuspended into 200 µL of PBS 185 
and stored in Protein LoBind tubes (Eppendorf) in -70 °C until analysis. 186 
2.5 Quantification and Size Determination of Particles in EV samples 187 
The concentration and size distribution of particles in EV samples was determined using 188 
Nanoparticle Tracking Analysis. The used LM14C model was equipped with 70 mW 189 
violet (405 nm) laser (Malvern Instruments Ltd., Malvern, UK) and sCMOS camera 190 
(Hamamatsu Photonics K.K., Hamamatsu, Japan). Data were captured using camera level 191 
14, and 3 videos of 90 seconds were recorded, manually mixing the sample between 192 
measurements. EV samples from PAS-B PCs were diluted 1:1000, 1:2000, 1:5000 and 193 
1:10000 with filtered (0.2 µm) PBS on d1, d2, d5 and d8 samples, respectively, and EV 194 
samples from PAS-E PCs were diluted 1:1000, 1:2000, 1:5000 and 1:5000 - 1:10000 on 195 
d1, d2, d5 and d8 samples, respectively. Data analysis was performed with threshold 5 196 
and gain 10. Data were recorded and analyzed with NanoSight software version 3.0 197 
(Malvern Instruments Ltd.). The data were reported as EV concentration of the PC on the 198 
sampling day by calculating the particle content of EV sample using the determined 199 
particle concentration and taking into account that the particles were isolated from 17 mL 200 
sample, considered as a representative sample of PC. 201 
2.6 Staining and Characterization of EV Samples on the ImageStreamX MkII 202 
EV samples from PAS-E were labelled with Alexa Fluor 488C5maleimide (Invitrogen, 203 
Carlsbad, CA, USA) for 60 minutes at RT as described previously [28]. Excess maleimide 204 
was removed by using exosome resin spin columns (Invitrogen) which were prepared 205 
according to manufacturer´s instructions. Maleimide labelling without EVs was 206 
performed in a parallel fashion to confirm the dye retention by columns and to get “mock” 207 
controls for the experiments. 208 
Different fluorescent stains for further characterization of EVs were used according to 209 
manufacturer´s instructions. Antibodies were: CD41a AF647 (clone HIP8 (BioLegend, 210 
San Diego, CA, USA)), CD45 PerCP-Cy5.5 (clone 2DI (BioLegend)), CD63 BV510 211 
(clone H5C6 (BD BioScience, San Jose, CA, USA)), and CD235a Pacific Blue (clone 212 
HI264 (BioLegend)). Apolipoprotein A contamination was surveyed with ApoA1 PerCP 213 
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(BioSite, Täby, Sweden). Antibodies were incubated for 30 minutes in RT in the dark in 214 
PBS. 215 
Maleimide488 and fluorescent positive EVs were detected using a 12 channel Amnis® 216 
ImageStream®X Mark II (EMD Millipore, Burlington, MA, USA) imaging flow 217 
cytometer. Samples were acquired at 60 × magnification with low flow rate/high 218 
sensitivity. The integrated software INSPIRE® (EMD Millipore) was used for data 219 
collection. The instrument and INSPIRE software were set up as follows: Excitation 220 
lasers 488, 642 and 785 and channels (Ch)01 and Ch09 (bright field), Ch06 (scattering 221 
channel), plus fluorescence channels Ch02, Ch05, Ch07, Ch08 and Ch011 were activated 222 
for signal detections. 223 
At least 10000 events for each sample were acquired. Positive events for maleimide488 224 
were gated based on the intensity values and used for further analysis. Single colour 225 
controls were used for compensation and unlabelled EVs were used to determine the auto 226 
fluorescence. Buffer with and without antibody/maleimide488 molecules were used to 227 
determine the background noise. Compensated data files were analysed using image-228 
based algorithms available in the IDEAS® statistical analysis software package (version 229 
6.2.188.0).  230 
2.7 Statistical Analysis 231 
Kruskal-Wallis test together with Dunn’s multiple comparison test to take into account 232 
the effect of multiple testing was used to determine the significance of the results within 233 
PASs, and p-values of < 0.05 (*), < 0.01 (**),< 0.001 (***), and < 0.0001 (****) were 234 
considered significant. To determine the significance between PASs on d5 sample Mann-235 
Whitney test together with Bonferroni correction was used, * = Bonferroni adjusted p < 236 
0.05. Spearman correlation coefficient and related p-value together with R2 value of the 237 
standard curve was used to determine the correlation between the different platelet 238 
activation parameters. All statistical analysis was performed using GraphPad Prism v. 239 
6.07 (GraphPad Software, Inc. La Jolla, CA, USA). 240 
3 Results 241 
3.1 CD62P Exposure of Platelets 242 
A statistically significant, time-dependent increase in the CD62P exposure was observed 243 
during the eight day storage period. The exposure of CD62P in the PAS-B stored platelets 244 
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increased from 8.5% to 78% (p = 0.0226 and 0.0002 on d5 and d8, respectively) when 245 
compared to the positive, thrombin activated control (Fig. 1A). In PAS-E platelets, the 246 
average CD62P exposure increased from 3.6% to 71% (p = 0.0028 on d8) compared to 247 
the positive control (Fig. 1A).  248 
When CD62P exposure was determined by comparison to the isotype control, the CD62P 249 
exposure of PAS-B platelets increased from 36% to 70% (p = 0.0177 and 0.0005 on d5 250 
and d8, respectively) and from 24% to 53% (p = 0.0117 on d8) in the PAS-E platelets 251 
(Fig. 1B).  252 
Regardless of the CD62P exposure determination method, on d5, the last day when the 253 
PC can be transfused to patients, platelets in PAS-B PCs exposed more CD62P than 254 
platelets in PAS-E PCs (Bonferroni adjusted p = 0.0016 for both, Fig. 1A and B)  255 
3.2 Content of sGPV in PCs 256 
The sGPV content of PAS-B PCs increased from the average of 2.1 to 24.5 pmol/109 257 
platelets during the storage (p = 0.0225 and 0.0002 on d5 and d8, respectively (Fig. 1C)). 258 
Also in the PAS-E PCs, the increase in sGPV was statistically significant, but more subtle, 259 
as the sGPV concentration increased from 1.8 to 12.1 pmol/109 platelets (p = 0.0224 and 260 
0.0002 on d5 and d8, respectively) during the 8 day storage (Fig. 1C). The sGPV content 261 
of PCs was significantly higher in PAS-B PCs than PAS-E PCs at d5 ( Bonferroni 262 
adjusted p = 0.0158, Fig. 1C). 263 
3.3 Concentration and Size Distribution of Particles in EV Samples 264 
The particle concentration in EV samples of PAS-B PCs significantly increased during 265 
the 8 day storage period from 1.1 × 1010 particles/mL on d1 to 1.3 × 1011 particles/mL on 266 
d8 (p = 0.0292 and 0.0021 on d5 and d8, respectively) and in the PAS-E PCs from 7.9 × 267 
109 particles/mL on d1 to 3.7 × 1010 particles/mL on d8 (p = 0.0019 and p < 0.0001 on d5 268 
and d8, respectively (Fig. 1D)). Both the PAS-B and PAS-E PCs initially had similar 269 
particle concentration in EV samples, but from d2 time point onwards the particle 270 
concentration in EV samples of PAS-B PCs was higher compared to PAS-E PCs 271 
(Bonferroni adjusted p = 0.016 on d5, Fig. 1D). 272 
The size distribution of particles in EV samples changed significantly during the aging 273 
only in the PAS-B PCs (Fig 1E). Initially, 61% of the particles were < 100 nm in diameter, 274 
but after 8 days of storage, the percentage of particles < 100 nm had decreased to 27% (p 275 
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= 0.0070). Consequently, the percentage of particles with a diameter of 101 – 200 nm was 276 
initially 31%, which increased to 56% at d8 (p = 0.0484). In contrast to PAS-B, no 277 
significant alteration in the size distribution of particles in EV samples was observed in 278 
PAS-E PCs (Fig. 1E). 279 
3.4. Characteristics of EV Isolated from PCs 280 
From all the maleimide-positive particles in the EV samples, the majority expressed 281 
CD41, indicating that the EVs isolated from the PCs are mainly derived from platelets. 282 
Also, EV-marker CD63 was abundantly present and the number of CD41 and CD63 283 
positive particles increased during the 7 day storage. Besides the platelet-derived 284 
particles, minute amounts of leukocyte- and erythrocyte-derived particles and ApoA1 285 
were detectable in the EV samples (Table 1). 286 
3.5 Correlation of EV Sample Particle Concentration with CD62P Exposure and 287 
sGPV Content 288 
A strong positive correlation was observed between the particle concentration of EV 289 
samples and the sGPV content of PCs (R2 = 0.7639, Spearman r = 0.7906 with p < 0.0001, 290 
Fig. 2A), and very strong positive correlation was observed between the particle 291 
concentration of EV samples and the CD62P exposure of platelets (R2 = 0.6626, 292 
Spearman r = 0.8269 with p < 0.0001, Fig. 2B), and between the sGPV content of PCs 293 
and the CD62P exposure of platelets (R2 = 0.8816, Spearman r = 0.9253 with p < 0.0001, 294 
Fig. 2C).  295 
4 Discussion 296 
For a few decades PCs have been prepared with PAS together with some plasma. Initially 297 
only plasma-containing PCs were favoured due to better functionality (estimated by the 298 
corrected count increments and bleeding) compared to only PAS-containing PCs [29]. 299 
The disadvantages of the plasma-containing PCs include increased incidences of adverse 300 
transfusion-related reactions, mainly allergic reactions, but possibly also transfusion-301 
related acute lung injury and ABO mismatched haemolysis [26]. Currently approximately 302 
30% of the volume of PAS-containing PCs still contain plasma to maintain platelet 303 
functionality [30], but the development of PAS has resulted in a notable improvement of 304 
platelet quality and functionality, leading to experimentations with decreased content of 305 
plasma in PCs with PAS [31]. At the moment PAS-E is considered to be the best PAS 306 
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developed, having similar platelet functionality to the PCs with plasma in terms of 307 
corrected count increment [29], and it has been even hypothesized whether with the 308 
addition of further components such as glucose [30], the advantage of plasma could be 309 
surpassed in favour of the PAS-only PCs. The driving force behind reducing the plasma 310 
content in PCs is the potential decline in the incidence of adverse transfusion-related 311 
reactions. Additionally, the leftover plasma could be utilized for fractionation to produce 312 
other tranfusable products [26].  313 
All common PASs contain NaCl and acetate [26]. NaCl is added in varying amounts to 314 
adjust the PC osmolarity, and acetate is added for two reasons: firstly, to provide an 315 
alternative energy source in addition to glucose, as it reduces lactate production and 316 
consequently influences the pH of the PC. Secondly, during the enzymatic processing of 317 
acetate carbon dioxide is formed, which further reacts with water to form bicarbonate 318 
providing increased buffer capacity to PCs [32]. Most PASs also contain citrate as 319 
anticoagulant, which provides yet another energy source, and added buffer capacity 320 
[26,33]. Furthermore, PAS-E contains phosphate, potassium, and magnesium whereas 321 
PAS-B does not [26]. Phosphate is added to PCs for improved buffer capacity and to 322 
stimulate platelet glycolysis [34]. PASs with different compositions have been 323 
extensively tested, and the addition of potassium and magnesium have been connected to 324 
decreased cytokine [35] and lactate [36,37] production, as well as decreased CD62P 325 
[37,38] and phosphatidylserine [38] exposure of platelets. Our results on time-dependent 326 
platelet activation are in line with these previous findings, as based on the three assessed 327 
platelet activation markers (CD62P exposure of platelets together with sGPV and EV 328 
content of PCs), platelets in PAS-B PCs were more activated than the PAS-E PC platelets 329 
on d5, the last day when PC could be transfused to patients. A significant increase in the 330 
activation state of the PAS-B platelets was detected with all three activation markers at 331 
d5 sampling. For PAS-E PCs a significant increase in the sGPV content and EV particle 332 
concentration was observed at d5 as well, whereas a significant increase in the CD62P 333 
exposure was observed only at d8. Although it is unclear how the altered PAS 334 
composition affects platelet activation, the mechanism might involve membrane 335 
potassium movement and permeability [39]. Similarly to CD62P and sGPV, a time-336 
dependent increase of EV concentration in PCs was observed, in line with previously 337 
published results [40,41]. Based on the current data EV concentration correlated well with 338 
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the sGPV content and the CD62P exposure of platelets, indicating that the EV 339 
concentration could be used to indicate platelet activation in PCs. 340 
As shown previously, determination of both the CD62P exposure of platelets and the 341 
sGPV content in PCs were sensitive and reproducible methods to detect platelet activation 342 
[6,27]. As an additional advantage of these methods, the maximum extent for both 343 
parameters can be determined, which helps to estimate the platelet activation state by 344 
giving either a relative or an absolute [42] boundary value (for CD62P and sGPV, 345 
respectively). Contrary to CD62P and sGPV measurements, it is not possible to generate 346 
an accurate control for a maximum EV production as different agonists produce varying 347 
amounts of platelet-derived EVs [23]. Although current PC manufacturing processes 348 
ensure minimal cell contamination, EVs from erythrocytes, platelets and leukocytes are 349 
present in PC already due to the plasma component of the PCs, as shown in this study and 350 
by others [14]. It is difficult to determine, whether the platelet-derived EVs are produced 351 
due to aging-related platelet activation, as a result of interaction of buffy coat components 352 
during the storage, or even apoptosis-like process [43]. The interaction of buffy coat EVs 353 
and platelets might explain the platelet activation to some degree [44] and consequently 354 
the high variation in the particle concentration of EV samples from PCs especially seen 355 
in the d8 samples. Additionally considering the variance in donors [45,46], current EV 356 
sample preparation methods [47] and the lack of standardized and accurate EV 357 
quantification methods [48–50], it must be stressed that although EV concentration seems 358 
as a potential marker of platelet activation, significant development and standardization 359 
will needed before the current methods could be replaced to determine platelet activation 360 
state in PCs. The authors would like to underline that EVs could still be used as a 361 
complementary platelet activation marker to CD62P and sGPV. 362 
In addition to EV concentration being a marker for platelet activation similarly to CD62P 363 
or sGPV, EVs could also provide qualitative information of PC aging and possibly even 364 
functionality. Besides influencing the size [23,51] and the molecular cargo [23,24,52] of 365 
produced EVs, platelet activating conditions have been shown to affect the subsequent 366 
function of produced EVs [53], and future studies could concentrate on the qualitative 367 
information provided by PC-derived EVs. In the current study, we observed a time-368 
dependent increase in the size distribution of particles in the EV samples from platelets 369 
stored in PAS-B. Since platelet activation was influenced by the PAS composition, it may 370 
also have an influence to the produced EVs. Another possible explanation to the altered 371 
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size could be an artefactual clumping of EVs, which has been shown previously [54]. 372 
However, the effect was only subtle compared to the size of e.g., EV doublets and without 373 
a corresponding decline in the particle concentration, so formation of stickier EVs is 374 
unlikely to explain the current results. A change in the EV population in the PC, reflected 375 
by the size change, could also have functional effects upon transfusion [55]. To 376 
understand the potential effects of EVs in storage lesion, adverse transfusion-related 377 
reactions, or immunomodulatory functions in general, it will be necessary to carefully 378 
examine the molecular composition of EV populations by lipidomics, proteomics, or 379 
metabolomics [56–58]. Moreover, characterizing the PC-derived EVs could be also a step 380 
towards personalized transfusion treatments, where patients could be targeted to receive 381 
PCs that would suit their needs the best [45,46], e.g., PCs that have more procoagulant 382 
potency in the case of severe bleeding. By doing this, the utilization of PCs could be 383 
optimized, leading to less wasted PCs and hopefully to transfusions with less adverse 384 
transfusion-related reactions.  385 
In conclusion, EVs may be useful tools in QC of PCs in the future, and the molecular 386 
characterization of EVs could provide more information about the state and usability of 387 
the PCs, ultimately benefitting the patients receiving transfusions. 388 
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7 Figure Legends 584 
Figure 1: Quality control markers used for the evaluation of platelet activation during 585 
storage of platelet concentrates with platelet additive solution (PAS-)B and PAS-E. Time-586 
dependent changes in the CD62P exposure of platelets, when compared to a positive (A) 587 
or an isotype control (B); soluble glycoprotein V (sGPV) production of platelets (C); 588 
concentration (D) and size distribution (E) of particles in the extracellular vesicle samples 589 
isolated from platelet concentrates. Statistical difference within a given PAS,is indicated 590 
with black and grey stars for PAS-B and PAS-E platelet concentrates, respectively, * = p 591 
< 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001 compared to day (d)1 using 592 
Kruskal-Wallis test with Dunn’s multiple comparison. Statistical difference between 593 
PAS-B and PAS-E platelet concentrates on d5, * = Bonferroni adjusted p < 0.05 using 594 
Mann-Whitney test with Bonferroni correction is indicated with a red star. Bars represent 595 
mean with standard deviation in A-D, columns present mean and bars standard deviation 596 
in E. Data were acquired in 3 independent experimental settings, n = 4-5 (PAS-B in all 597 
figures, PAS-E in A and B) or 10 (PAS-E in C, D, and E). 598 
Figure 2: Correlation analysis of the three different markers for platelet activation: 599 
particle concentration in the extracellular vesicle samples and sGPV production of 600 
platelets (A); particle concentration in the extracellular vesicle samples and CD62P 601 
exposure of platelets, when compared to positive control (B); sGPV production and 602 
CD62P exposure of platelets (comparison to a positive control) (C). Figure was compiled 603 
using data from both platelet additive solution B and E platelet concentrates acquired 604 
from 3 independent experimental settings. 605 
Table 1: Frequency (%) of surface markers identified from maleimide-positive particles 606 
of EV samples isolated from platelet concentrate on day 1 and day 8. 607 
